Главная › Плоскоклеточный рак головы и шеи › Калифорния › Los Angeles
Клинические исследования Плоскоклеточный рак головы и шеи в городе Los Angeles, CA
42 исследований по теме Плоскоклеточный рак головы и шеи ищут участников в центрах в городе Los Angeles и поблизости (в радиусе около 30 миль). Откройте исследование, чтобы узнать критерии участия и контакты исследовательской группы.
Официальный текст исследования (на английском)
Ищете участников для исследования? Разместите его вверху страницы — $99 на 30 дней →
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Набор участниковФаза 3
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Набор участниковФаза 1
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Набор участниковФаза 2/3
- Site #0106, Los Angeles
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Набор участниковФаза 1
- Ronald Reagan UCLA Medical Center, Los Angeles
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Набор участниковФаза 1
- Research Site, Los Angeles
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Набор участниковФаза 3
- Valkyrie Clinical Trials, Los Angeles
- University of California, Los Angeles UCLA, Los Angeles
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Набор участниковФаза 2
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Набор участниковФаза 2
- The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
- и еще 1
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Набор участниковФаза 3
- UCLA Hematology Oncology, Los Angeles
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Набор участниковФаза 1/2
- University of Southern California, Los Angeles
Intratumoral N17350 in Advanced Solid Tumors
Набор участниковФаза 1/2
- The Angeles Clinic and Research Institute, Los Angeles
- UCLA - Jonsson Comprehensive Cancer Center, Los Angeles
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Набор участниковФаза 2
- Kaiser Permanente Los Angeles Medical Center, Los Angeles
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Набор участниковФаза 1
- Site 105 - START Los Angeles, Los Angeles
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Набор участниковНаблюдательное исследование
- USC/Norris Comprehensive Cancer Center, Los Angeles
- University of California, Los Angeles, Los Angeles
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
Набор участниковФаза 1/2
- START Los Angeles, Los Angeles
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Набор участниковФаза 1
- University of Southern California, Los Angeles
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Набор участниковФаза 2
- University of California Los Angeles, Los Angeles
- Samuel Oschin Cancer Center, Los Angeles
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Набор участниковФаза 1/2
- USC/Norris Comprehensive Cancer Center, Los Angeles
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
Набор участниковФаза 3
- USC / Norris Comprehensive Cancer Center, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Набор участниковФаза 1/2
- USC Norris Comprehensive Cancer Center, Los Angeles
SMP-3124LP in Adults With Advanced Solid Tumors
Набор участниковФаза 1/2
- Cedars Sinai Medical Center, Los Angeles
A Study of MGC026 in Participants With Advanced Solid Tumors
Набор участниковФаза 1
- The Angeles Clinic and Research Institute, Los Angeles
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Набор участниковФаза 1/2
- Los Angeles Cancer Network, Los Angeles
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Набор участниковФаза 1/2
- California Research Institute, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Набор участниковФаза 1/2
- Ellison Clinic at Saint John's, Los Angeles
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Набор участниковФаза 1
- Ronald Reagan UCLA Medical Center, Los Angeles
- The Regents of the University of California, Los Angeles
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Набор участниковФаза 1/2
- USC Norris Comprehensive Cancer Center, Los Angeles
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Набор участниковФаза 1
- USC Norris Comprehensive Cancer Center /ID# 279603, Los Angeles
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Набор участниковФаза 1
- Start Lacn, Los Angeles
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Набор участниковФаза 3
- GSK Investigational Site, Los Angeles
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Набор участниковФаза 2
- USA06-0, Los Angeles
- USA16-0, Los Angeles
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Набор участниковФаза 3
- University of California Los Angeles, Los Angeles
A Study of VET3-TGI in Patients With Solid Tumors
Набор участниковФаза 1
- USC/Norris Comprehensive Cancer Center, Los Angeles
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Набор участниковФаза 1
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Набор участниковФаза 1
- USC - Norris Comprehensive Cancer Center, Los Angeles
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Набор участниковФаза 1/2
- University of Southern California, Los Angeles
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Набор участниковФаза 1/2
- Research Site 125, Los Angeles
- Research Site 133, Los Angeles
- Research Site 103, Los Angeles
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Набор участниковФаза 1/2
- University of Southern California, Los Angeles
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Набор участниковФаза 1/2
- Cedars Sinai Medical Center, Los Angeles
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Набор участниковФаза 1/2
- UCLA Medical Center, Los Angeles
A Study of NX-1607 in Adults With Advanced Malignancies
Набор участниковФаза 1
- University of Southern California, Los Angeles
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Набор участниковФаза 1
- Keck School of Medicine of USC, Los Angeles
- UCLA, Los Angeles
Исследования Плоскоклеточный рак головы и шеи в других городах
- Houston, TX47 исследований
- Boston, MA40 исследований
- Nashville, TN39 исследований
- New York City, NY39 исследований
- St. Louis, MO28 исследований
- Arlington, VA26 исследований
- Philadelphia, PA26 исследований
- Chicago, IL26 исследований
- Atlanta, GA24 исследований
- San Antonio, TX22 исследований
- Pittsburgh, PA22 исследований
- New Haven, CT22 исследований
Другие исследования в городе Los Angeles
- Немелкоклеточный рак легкого87 исследований
- Рак (все виды)74 исследований
- Рак молочной железы73 исследований
- Рак простаты61 исследование
- Колоректальный рак59 исследований
- Метастатический рак57 исследований
- Рак яичников50 исследований
- Рак легких45 исследований
- Рак поджелудочной железы35 исследований
- Рак эндометрия34 исследований
- Меланома34 исследований
- Тройной негативный рак молочной железы27 исследований
Источник: ClinicalTrials.gov, данные получены 6 окт. 2026 г.. Каждая исследование устанавливает свои критерии участия; решение о включении принимает исследовательская группа.